<DOC>
	<DOCNO>NCT00661388</DOCNO>
	<brief_summary>This single arm study ass efficacy safety subcutaneous methoxy polyethylene glycol-epoetin beta ( Mircera ) correction maintenance hemoglobin level predialysis patient renal anemia currently treat erythropoietin stimulate agent ( ESA ) . Eligible patient receive monthly subcutaneous injection Mircera initial recommend dose 1.2 micrograms/kg . The anticipated time study treatment 3-12 month , target sample size 100-500 individual .</brief_summary>
	<brief_title>A Study Monthly Subcutaneous Mircera Treatment Chronic Renal Anemia Predialysis Patients Not Treated With ESA .</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<criteria>adult patient , &gt; =18 year age ; chronic renal anemia ; predialysis stage ; ESA therapy previous 3 month . transfusion red blood cell previous 2 month ; poorly control hypertension require hospitalization previous 6 month ; significant acute chronic bleeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>